Tigly (Tigecycline 50 mg Injection)

Overview:

TIGLY Injection contains Tigecycline, a glycylcycline, prevents incorporation of amino acid residues into elongating peptide chains. Tigecycline is not affected by the two major tetracycline resistance mechanisms, ribosomal protection and efflux. Accordingly, tigecycline has demonstrated in vitro and in vivo activity against a broad spectrum of bacterial pathogens. There has been no cross resistance observed between tigecycline and other antibiotics. Tigecycline is not affected by resistance mechanisms such as beta-lactamases (including extended spectrum beta-lactamases), target site modifications, macrolide efflux pumps or enzyme target changes (e.g. gyrase/topoisomerase).

 

 

 


Tigecycline belong to the class of glycylcycline, which is the an antimicrobial.

TIGLY Injection can be used in the treatment of the following conditions:

  • Complicated intra-abdominal infections
  • Complicated skin and skin structure infections
  • Community acquired pneumonia
  • Acute myeloid leukemia


Two TIGLY Injections by IV infusion initially, then 50 mg TIGLY Injection by IV infusion every 12 hours for 5-14 days, or as directed by Physician.
Tigecycline which inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome.